Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb suffers at hands of generic Plavix

October 26, 2006
Sales and Marketing

Figures show that the launch of a generic competitor to Plavix in the US dealt a serious blow to Bristol-Myers …

News

Takeda launches Actos combination in UK

October 26, 2006
Sales and Marketing

 Takeda has expanded its type II diabetes portfolio in the UK with the launch of Competact, a combination of the …

News

Cerovive failure another blow for AstraZeneca

October 26, 2006
Research and Development, Sales and Marketing AstraZeneca, Cerovive, neuroscience

 A drug which had held out the promise of reducing the disabling effects of stroke on patients will be abandoned …

News

Lilly underlines its position as major biotech company

October 25, 2006
Research and Development

Eli Lilly has opened the first phase of a $560 million expansion to its US biotech research complex.The news comes …

News

Freedom to Prescribe v The Formulary

October 24, 2006
GP, NHS, doctors, healthcare

The modern concept of a formulary embraces three basic principles: first, it is a limited list of treatments chosen from …

Feature

EU recommends first ever therapy for Hunter syndrome

October 24, 2006
Sales and Marketing

Shire has received full EU recommendation for the use of Elaprase for the long-term treatment of patients with Hunter syndrome.Marketing …

News

Industry calls for global healthcare systems to be benchmarked

October 13, 2006
Sales and Marketing

Fred Hassan, chief executive of Schering-Plough and new head of an international pharma industry organisation, has called for greater transparency …

News

New schizophrenia treatment promises no weight gain side-effects

October 13, 2006
Sales and Marketing

Solvay and Wyeth have filed a new treatment for schizophrenia with the US regulators, which promises to be free of …

News

Watchdog urges NHS to ‘raise its game’

October 12, 2006

An NHS watchdog has told managers the health service must raise its game following a national review of performance revealed …

News

From surgery to pharmacy

October 12, 2006
Sales and Marketing P, POM, marketing, reclassification, sales

Feature

Pfizer buys British vaccine company PowderMed

October 12, 2006
Research and Development Pfizer, Powdermed, vaccines

Pfizer will gain entry into the fast-growing vaccines market by buying PowderMed, the British company developing next generation products in …

News

Alzheimer’s drug ruling ”a terrible decision”

October 11, 2006
Sales and Marketing

Campaigners are stunned at NICE's final decision not to allow Alzheimer's drugs to be prescribed on the NHS in the …

News

Takeda retains The Remedy for European events

October 6, 2006
Medical Communications

Takeda Europe has re-appointed marketing firm The Remedy to run its pan-European and international meetings for 2007.The Remedy, which is …

News

Amgen to acquire Avidia

October 5, 2006
Research and Development, Sales and Marketing

Amgen is to pay $290 million to buy Avidia, a Californian biotech company which is developing innovative new protein-based medicines.Based …

News

General practice reaps rewards of contract

October 2, 2006

GPs and patients are continuing to reap the rewards of the new general practice contract, with doctors hitting targets for …

News

Novartis’ MS drug shows further promise

October 2, 2006
Research and Development

A new treatment for multiple sclerosis currently being developed by Novartis has shown further promise in slowing the progress of …

News

Transparently beneficial?

October 2, 2006
Medical Communications, Sales and Marketing industry relations, key opinion leaders, pharma

The pharma industry is under greater pressure than ever before to adopt an acceptable and ethical way of doing business, …

Feature

Pharmacists unhappy with Pfizer’s new UK supply chain

September 29, 2006
Manufacturing and Production

Pfizer has announced a radical overhaul of how it distributes its medicines to community pharmacists and dispensing doctors in the …

News

Novartis submits next generation blood pressure drug

September 29, 2006
Sales and Marketing

Next generation hypertension drug Rasilez has been submitted for EU approval.If approved, Rasilez will be the first ever renin inhibitor, …

News

Two new AstraZeneca laboratories opened in UK

September 29, 2006
Research and Development

AstraZeneca has officially opened two major research laboratories in the UK, which it says demonstrates its commitment to R&D in …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025